cyproheptadine has been researched along with Hyperparathyroidism in 1 studies
Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.
cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.
Hyperparathyroidism: A condition of abnormally elevated output of PARATHYROID HORMONE (or PTH) triggering responses that increase blood CALCIUM. It is characterized by HYPERCALCEMIA and BONE RESORPTION, eventually leading to bone diseases. PRIMARY HYPERPARATHYROIDISM is caused by parathyroid HYPERPLASIA or PARATHYROID NEOPLASMS. SECONDARY HYPERPARATHYROIDISM is increased PTH secretion in response to HYPOCALCEMIA, usually caused by chronic KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study we evaluated the influence of cyproheptadine treatment on serum PTH values, as well as serum Ca, Mg and P levels in patients with primary hyperparathyroidism." | 7.66 | Failure of cyproheptadine to affect calcium homoeostasis and PTH levels in primary hyperparathyroidism. ( Adalar, N; Gedik, O; Koray, Z; Telatar, F; Usman, A, 1983) |
| "In this study we evaluated the influence of cyproheptadine treatment on serum PTH values, as well as serum Ca, Mg and P levels in patients with primary hyperparathyroidism." | 3.66 | Failure of cyproheptadine to affect calcium homoeostasis and PTH levels in primary hyperparathyroidism. ( Adalar, N; Gedik, O; Koray, Z; Telatar, F; Usman, A, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gedik, O | 1 |
| Usman, A | 1 |
| Telatar, F | 1 |
| Adalar, N | 1 |
| Koray, Z | 1 |
1 other study available for cyproheptadine and Hyperparathyroidism
| Article | Year |
|---|---|
Failure of cyproheptadine to affect calcium homoeostasis and PTH levels in primary hyperparathyroidism.
Topics: Calcium; Cyproheptadine; Homeostasis; Humans; Hyperparathyroidism; Magnesium; Parathyroid Hormone; P | 1983 |